New progress in the collection of proprietary Chinese medicines! The reporting phase has been entered

【Pharmaceutical Network Industry News】The national collection of proprietary Chinese medicines has attracted much attention from the industry, and new progress has come in
recent days.

On September 20, Hubei Pharmaceutical Price and Bidding Procurement Management Service Network issued the "Notice of the National Proprietary Chinese Medicine Joint Procurement Office on Filling in the Relevant Procurement Data of the Procurement Range of Proprietary Chinese Medicine Alliance", which clarifies that from 0:00 on September 22, 2022 to 24:00 on September 30, 2022, the time
for medical institutions will be filled in.

After the completion of the reporting time, no supplementary data reports
will be accepted.

The Notice requires that the historical procurement volume reported by medical institutions shall not be lower than the actual procurement volume of the procurement platform in 2021 in principle; If the completed procurement demand does not reach 80% of the historical procurement volume, it shall be reported
after data correction or submission of relevant explanations.

According to the "National Proprietary Chinese Medicine Alliance Procurement Announcement (No.
1 of 2022)" released on September 9, the second batch of procurement varieties of the Chinese Proprietary Medicine Alliance led by Hubei has a total of 16 categories and 42 products
.

The provinces include Hubei Province, Beijing Municipality, Tianjin Municipality, Hebei Province, Shanxi Province, Inner Mongolia Autonomous Region, Liaoning Province, Jilin Province, Heilongjiang Province, Shanghai Municipality, Jiangsu Province, Zhejiang Province, Anhui Province, Jiangxi Province, Shandong Province, Henan Province, Guangdong Province, Guangxi Zhuang Autonomous Region, Hainan Province, Chongqing Municipality, Sichuan Province, Guizhou Province, Yunnan Province, Tibet Autonomous Region, Shaanxi Province, Gansu Province, Qinghai Province, Ningxia Hui Autonomous Region, Xinjiang Uygur Autonomous Region, Xinjiang Production and Construction Corps, etc
。
At present, in addition to Hubei Province, Ningxia, Beijing, Shanxi and other places have also responded
.

On September 21, the Medical Insurance Bureau of Ningxia Hui Autonomous Region issued the "Notice on Filling in the Data of the Second Batch of Centralized Procurement of Drugs of Hubei Proprietary Chinese Medicine Alliance", which identified 15 varieties to participate, including compound cantharid, compound thrombosis, coronary heart ning, huatoxin, elderberry 7%, Lemai, vasculature, brain an, Garcinia cambogia, Xiangdan, Xinkeshu, Xingnajing, Ginkgo Damo, Ginkgo biloba leaf extract, and Zhenyuan
.

On September 20, the Beijing Municipal Medical Insurance Bureau issued the Notice of the Beijing Municipal Medical Security Bureau on Filling in the Relevant Procurement Data and Information of the Scope of Procurement Varieties of the Chinese Proprietary Medicine Alliance
.

The notice makes it clear that medical institutions shall, in accordance with the catalogue of varieties and refer to the historical procurement data of the procurement platform, truthfully fill in the historical purchase volume, purchase price and purchase amount of each product actually used in 2021; Combined with historical use, clinical drug demand and other factors, accurately fill in the procurement demand of each product in the next year, and explain
the products that are significantly different from the historical procurement demand filled in.

In addition, the Shanxi Provincial Medical Insurance Bureau has also issued a notice to clearly start filling in the relevant procurement data and information of the scope of procurement varieties of the National Proprietary Chinese Medicine Alliance
.

The industry generally believes that with the advancement of the collection of proprietary Chinese medicines in various places, the proprietary Chinese medicine market may be reshuffled
.

From the perspective of the decline forecast, there have been pilots in previous places, such as the collection of proprietary Chinese medicines in 19 provinces such as Hubei, and the collection of proprietary Chinese medicines in 6 provinces such as Guangdong, etc.
From the results of collection, the average reduction is below
50%.

In this regard, the industry believes that the price reduction of this collection and mining will also be relatively mild
.

Xiangcai Securities pointed out in the research report that the national collection and collection of proprietary Chinese medicines and the normalization of subsequent collection and procurement have become an inevitable trend, the concentration of the industry is expected to be further improved, and the leading enterprises and exclusive varieties of proprietary Chinese medicines are expected to benefit greatly and realize the exchange of price for volume
.

Disclaimer: Under no circumstances does the information herein or the opinions expressed in this article constitute investment advice
to any person.